2023
Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)—a systematic review and individual patient data meta-analysis
Chow R, Yin L, Baqri W, Huang R, Boldt G, Younus J, Lock M, Prsic E, Zimmermann C, Herrstedt J. Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)—a systematic review and individual patient data meta-analysis. Supportive Care In Cancer 2023, 31: 505. PMID: 37535218, DOI: 10.1007/s00520-023-07978-y.Peer-Reviewed Original ResearchMeSH KeywordsAntiemeticsAntineoplastic AgentsHumansNauseaNeoplasmsPrevalenceProspective StudiesVomitingConceptsChemotherapy-induced nauseaIndividual patient dataDay 4Individual patient-level dataPatient dataPatient-level dataStepwise logistic regressionEmetogenic chemotherapyChemotherapy regimenChemotherapy regimensPatient demographicsCochrane CENTRALResultsA totalOverall prevalenceCINVNauseaVomitingPatientsEligible articlesSystematic reviewAntineoplastic agentsStudy authorsLogistic regressionMethodsThis reviewSignificant risk
2021
Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis
Chow R, Navari RM, Terry B, DeAngelis C, Prsic EH. Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis. Supportive Care In Cancer 2021, 30: 1015-1018. PMID: 34613472, DOI: 10.1007/s00520-021-06606-x.Peer-Reviewed Original Research